Iridex Corporation (NASDAQ: IRIX) is a globally recognized leader in the development, manufacturing, and marketing of innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. Founded in 1989 and headquartered in Mountain View, California, the company has extended its strong presence to over 100 countries.
Iridex’s solutions, renowned for safety and effectiveness, focus mainly on treating sight-threatening eye conditions, specifically age-related macular degeneration, glaucoma, and retinal diseases. Their core products are laser consoles, delivery devices, and a range of single-use disposable consumables.
The company's flagship product line is the IQ Series of lasers, an innovative technological platform that emphasizes simplicity, versatility, robustness, and affordability. Additionally, the delivery devices include a variety of patented laser probes and several groundbreaking devices – G-Probe, G-Probe Shields, and G-Probe Illuminate - to simplify the treatment of excessive eye pressure (glaucoma).
Iridex has positioned itself as a pioneer in MicroPulse, a tissue-sparing laser therapy that allows physicians to treat more types of patients with fewer side effects. MicroPulse procedure offers an excellent alternative for patients diagnosed with various retinal diseases and glaucoma and mitigates the risks associated with conventional continuous-wave laser therapy.
With a mission to improve people’s lives by preserving or improving their sight, Iridex has installed over 11,000 systems worldwide and treats over 1 million patients per year.
Iridex's financial stability, driven by its strategic focus and customer obsession, allows it to consistently invest in research and development. This has resulted in a growing patent portfolio and a pipeline of products that address the emerging needs of its target market. The company is financially resilient with a robust revenue growth trend, consistently strong balance sheets, and a proven track record of profitability.
In a nutshell, Iridex Corporation demonstrates a stellar combination of innovation, quality, and genuineness in aiming to halt or reverse the world's leading causes of blindness. Its market-leading position and commitment to clinical education and services ensure it will continue serving as an invaluable partner to physicians worldwide, promoting sight preservation and enhancement.